CHICAGO (EGMN) - Endocrinologists who prescribe vascular endothelial growth factor receptor tyrosine kinase inhibitors for their patients with refractory thyroid cancer will have to manage side effects they are not used to dealing with, according to Dr. Yariv Houvras.The side effects common to the tyrosine kinase inhibitors (TKIs) as a class are fatigue, diarrhea, rash, and hypertension. "Fatigue is the single biggest problem we have; it can be completely debilitating to these patients. In my experience,...